It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
G-protein coupled inwardly rectifying potassium (GIRK) channels are key players in inhibitory neurotransmission in heart and brain. We conducted molecular dynamics simulations to investigate the effect of a selectivity filter (SF) mutation, G154S, on GIRK2 structure and function. We observe mutation-induced loss of selectivity, changes in ion occupancy and altered filter geometry. Unexpectedly, we reveal aberrant SF dynamics in the mutant to be correlated with motions in the binding site of the channel activator Gβγ. This coupling is corroborated by electrophysiological experiments, revealing that GIRK2wt activation by Gβγ reduces the affinity of Ba2+ block. We further present a functional characterization of the human GIRK2G154S mutant validating our computational findings. This study identifies an allosteric connection between the SF and a crucial activator binding site. This allosteric gating mechanism may also apply to other potassium channels that are modulated by accessory proteins.
Gly selectivity filter (TIGYGYR) mutant of the GIRK2 channel causes rare but severe neurological disorder called the Keppen-Lubinsky syndrome. Here, the authors explore the molecular mechanism of action of this glycine to serine mutant causing disease and identify an allosteric connection between the selectivity filter and a crucial activator binding site.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details




1 University of Vienna, Department of Pharmaceutical Sciences, Division of Pharmacology and Toxicology, Vienna, Austria (GRID:grid.10420.37) (ISNI:0000 0001 2286 1424)
2 Tel Aviv University, Department of Physiology and Pharmacology, School of Medicine, Tel Aviv, Israel (GRID:grid.12136.37) (ISNI:0000 0004 1937 0546); Indian Institute of Technology Madras, Department of Biotechnology, Bhupat and Jyoti Mehta School of Biosciences, Chennai, India (GRID:grid.417969.4) (ISNI:0000 0001 2315 1926)
3 Tel Aviv University, Department of Physiology and Pharmacology, School of Medicine, Tel Aviv, Israel (GRID:grid.12136.37) (ISNI:0000 0004 1937 0546)
4 Indian Institute of Technology Madras, Department of Biotechnology, Bhupat and Jyoti Mehta School of Biosciences, Chennai, India (GRID:grid.417969.4) (ISNI:0000 0001 2315 1926)
5 Tel Aviv University, Department of Physiology and Pharmacology, School of Medicine, Tel Aviv, Israel (GRID:grid.12136.37) (ISNI:0000 0004 1937 0546); Tel Aviv University, Sagol School of Neuroscience, Tel Aviv, Israel (GRID:grid.12136.37) (ISNI:0000 0004 1937 0546)